Clinical Trial Update: OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

View source ↗

Summary

This entry reports the OSIREAL real-world evidence trial of Osimertinib for EGFR-mutant non-small cell lung cancer in Spain, sponsored by AstraZeneca, and curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Status: RECRUITING